Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition

Recipients of allogeneic haematopoietic stem cell transplants (HSCT) can develop acute or chronic, or both forms of graft-versus-host disease (a/cGvHD), whereby immune cells of the donor attack host tissues. Steroids are the primary treatment, but patients with severe, refractory disease have limite...

Full description

Bibliographic Details

Published in:	Cochrane database of systematic reviews Vol. 1; p. CD009768
Main Authors:	Fisher, Sheila A, Cutler, Antony, Doree, Carolyn, Brunskill, Susan J, Stanworth, Simon J, Navarrete, Cristina, Girdlestone, John
Format:	Journal Article
Language:	English
Published:	England 30.01.2019
Subjects:	Acute Disease beta-Thalassemia - therapy Chronic Disease Graft vs Host Disease - epidemiology Graft vs Host Disease - therapy Hematologic Neoplasms - mortality Hematologic Neoplasms - therapy Hematopoietic Stem Cell Transplantation - adverse effects Humans Incidence Mesenchymal Stem Cell Transplantation - mortality Randomized Controlled Trials as Topic Recurrence
ISSN:	1469-493X, 1469-493X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!